Avenue Therapeutics up on meeting FDA to discuss drug administration study

Avenue Therapeutics

09/03/2023 10:50

** Avenue Therapeutics Inc  ATVI.O  soars 30.7% to $1.36
premarket
    ** Co says it will participate in a meeting with the U.S.
Food and Drug Administration (FDA) to discuss a proposed study
to assess the risk associated with IV administration of a
already approved pain relief drug, tramadol  urn:newsml:reuters.com:*:nGNX5DhYZ2
    ** ATXI expects to provide an update on the outcome of the
meeting in April 2023
    ** Last September, co already conducted meeting with the FDA
for the same; based on the regulator's suggestion, it had
submitted a request for another meeting
    ** ATXI was down ~91% last year

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))